Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Dr. Allen F. Ryan Ph.D.

Co-Founder and Member of the Advisory Panel

Mr. Paul E. Cayer

Chief Financial & Bus. Officer

Dr. David Allen Weber

Pres, Chief Executive Officer & Director

Mr. David  Skarinsky

Senior Vice President of Clinical

Ms. Barbara M. Finn

Senior Vice President of Regulatory Affairs & Quality Assurance

Mr. James  Branch CPA

Vice President of Fin. & Controller

Pres, Chief Financial & Bus. Officer and Sec.

Ms. Breianna  Bowen

Vice President of HR

Dr. Jeffery J. Anderson Ph.D.

Vice President of Clinical Sciences

Dr. Fabrice  Piu Ph.D.

Senior Vice President of Preclinical Devel.

Dr. Rick Adam Friedman M.D., Ph.D.

Dr. Alan Charles Foster Ph.D.

Chief Scientific Officer

Biotechnologie

Otonomy, Inc.

Otonomy, Inc. Structure de gestion

Informations sur la direction